LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC

ClinicalTrials.gov ID: NCT04759664

Public ClinicalTrials.gov record NCT04759664. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Topically Administered LUT014 in Metastatic Colorectal Cancer Patients With EGFR Inhibitor Induced Acneiform Lesions

Study identification

NCT ID: NCT04759664
Recruitment status: Not listed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Lutris Pharma Ltd.; Industry
Enrollment: 117 participants

Conditions and interventions

Conditions

EGFRI Induced Acneiform Lesions

Interventions

LUT014 Gel (Dose 1) Drug
LUT014 Gel (Dose 2) Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 11, 2021
Primary completion: Feb 29, 2024
Completion: Apr 30, 2024
Last update posted: Oct 5, 2023

2021 – 2024

United States locations

U.S. sites: 17
U.S. states: 11
U.S. cities: 15

Facility	City	State	ZIP	Site status
Innovative Clinical Research Institute	Glendale	California	91204	Recruiting
UCLA	Santa Monica	California	90404	Recruiting
Miami Dermatology & Laser Research	Miami	Florida	33173	Recruiting
Miami Dermatology and Laser Institute	Miami	Florida	33173	Recruiting
Moffit Cancer Center	Tampa	Florida	33637	Recruiting
Appalachian Regional Healthcare	Hazard	Kentucky	41701	Recruiting
Willis-Knighton Cancer Center	Shreveport	Louisiana	71103	Recruiting
Dana Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
Hackensack Meridian Health	Neptune City	New Jersey	07753	Recruiting
Memorial Sloane Kettering	New York	New York	10065	Recruiting
New York Cancer and Blood Specialists	New York	New York	11776	Recruiting
The Christ Hospital	Cincinnati	Ohio	45219	Recruiting
Fox Chase Cancer Center	Philadelphia	Pennsylvania	19111	Recruiting
UPMC Hillman Cancer Center Investigational Drug Service	Pittsburgh	Pennsylvania	15232	Recruiting
The University of Texas MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
Providence Regional Cancer Partnership	Everett	Washington	98201	Not yet recruiting
MultiCare Institute for Research and Innovation	Tacoma	Washington	98405	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04759664, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 5, 2023 · Synced Jul 23, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04759664 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →